151 related articles for article (PubMed ID: 34711530)
1. Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States.
Lewicki P; Arenas-Gallo C; Qiu Y; Venkat S; Basourakos SP; Scherr D; Shoag JE
Eur Urol Focus; 2022 Jul; 8(4):968-971. PubMed ID: 34711530
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.
Pietzak EJ
Curr Urol Rep; 2017 May; 18(5):39. PubMed ID: 28324275
[TBL] [Abstract][Full Text] [Related]
4. Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer.
Elbæk SK; Andreasen TG; Taber A; Young-Halvorsen K; Neijber A; Jensen JB; Dyrskjøt L
Eur Urol Open Sci; 2023 Dec; 58():37-46. PubMed ID: 38152487
[TBL] [Abstract][Full Text] [Related]
5. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.
Daneshmand S; Bazargani ST; Bivalacqua TJ; Holzbeierlein JM; Willard B; Taylor JM; Liao JC; Pohar K; Tierney J; Konety B;
Urol Oncol; 2018 Aug; 36(8):361.e1-361.e6. PubMed ID: 29859728
[TBL] [Abstract][Full Text] [Related]
6. Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer.
Mariappan P; Rai B; El-Mokadem I; Anderson CH; Lee H; Stewart S; Donat R
Urology; 2015 Aug; 86(2):327-31. PubMed ID: 26142924
[TBL] [Abstract][Full Text] [Related]
7. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.
Lotan Y; Bivalacqua TJ; Downs T; Huang W; Jones J; Kamat AM; Konety B; Malmström PU; McKiernan J; O'Donnell M; Patel S; Pohar K; Resnick M; Sankin A; Smith A; Steinberg G; Trabulsi E; Woods M; Daneshmand S
Nat Rev Urol; 2019 Jun; 16(6):377-386. PubMed ID: 31019310
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
[TBL] [Abstract][Full Text] [Related]
9. Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials.
Sari Motlagh R; Mori K; Laukhtina E; Aydh A; Katayama S; Grossmann NC; Mostafai H; Pradere B; Quhal F; Schuettfort VM; Roshandel MR; Karakiewicz PI; Teoh J; Shariat SF; Fajkovic H
BJU Int; 2021 Sep; 128(3):280-289. PubMed ID: 33683778
[TBL] [Abstract][Full Text] [Related]
10. Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Klaassen Z; Li K; Kassouf W; Black PC; Dragomir A; Kulkarni GS
Can Urol Assoc J; 2017 Jun; 11(6):173-181. PubMed ID: 28652875
[TBL] [Abstract][Full Text] [Related]
11. Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
Lacetera V; Cantoro U; Montesi L; Cantoro D; Cervelli B; Cicetti A; Gabrielloni G; Milella D; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
Arch Ital Urol Androl; 2017 Mar; 89(1):39-41. PubMed ID: 28403596
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy.
Pagliarulo V; Alba S; Gallone MF; Di Stasi S; Cormio L; Petitti T; Buscarini M; Minafra P; Carrieri G
J Endourol; 2017 Apr; 31(4):405-411. PubMed ID: 28145751
[TBL] [Abstract][Full Text] [Related]
13. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
14. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
[TBL] [Abstract][Full Text] [Related]
15. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
[TBL] [Abstract][Full Text] [Related]
16. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer.
Williams SB; Gavaghan MB; Fernandez A; Daneshmand S; Kamat AM
Urol Oncol; 2022 Jan; 40(1):10.e7-10.e12. PubMed ID: 34158205
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
Shore ND; Gavaghan MB
Urol Oncol; 2023 Apr; 41(4):207.e9-207.e16. PubMed ID: 36564259
[TBL] [Abstract][Full Text] [Related]
18. Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review.
Maisch P; Koziarz A; Vajgrt J; Narayan V; Kim MH; Dahm P
BJU Int; 2022 Dec; 130(6):730-740. PubMed ID: 35238145
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses.
Soorojebally Y; Neuzillet Y; Lebret T; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Lamy PJ; Oudard S; Rébillard X; Roy C; Roumiguié M; Rouprêt M; Audenet F
Prog Urol; 2023 May; 33(6):307-318. PubMed ID: 37088584
[TBL] [Abstract][Full Text] [Related]
20. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
Daneshmand S; Schuckman AK; Bochner BH; Cookson MS; Downs TM; Gomella LG; Grossman HB; Kamat AM; Konety BR; Lee CT; Pohar KS; Pruthi RS; Resnick MJ; Smith ND; Witjes JA; Schoenberg MP; Steinberg GD
Nat Rev Urol; 2014 Oct; 11(10):589-96. PubMed ID: 25245244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
